Patents Assigned to Neurocrine Biosciences
  • NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
    Publication number: 20110166116
    Abstract: New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.
    Type: Application
    Filed: June 23, 2010
    Publication date: July 7, 2011
    Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, NEUROCRINE BIOSCIENCES, INC.
    Inventors: Brian DYCK, Joe A. TRAN, Junko TAMIYA, Florence JOVIC, Troy VICKERS, Chen CHEN, Nicole HARRIOTT, Timothy COON, Neil J. ASHWEEK
  • COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
    Publication number: 20110021491
    Abstract: New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein X1, X2, X3, X4, Y1, Y2, A, R1, R2, R3, R4, m, n, p, and q are as defined herein, including stereoisomers, esters, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof in a patient in need thereof.
    Type: Application
    Filed: June 23, 2010
    Publication date: January 27, 2011
    Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, NEUROCRINE BIOSCIENCES, INC.
    Inventors: Joe A. TRAN, Chen CHEN
  • CRF receptor antagonists and methods relating thereto
    Patent number: 7652035
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2, n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: January 26, 2010
    Assignees: Neurocrine Bioscience, Inc., SB Cork
    Inventors: Marion Lanier, Manisha Moorjani, John Edward Tellew, John P. Williams
  • Pyrazolo [1,5-Alpha] Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
    Publication number: 20080306092
    Abstract: The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine. The present invention also relates to pharmaceutical compositions comprising the same and methods of using the same.
    Type: Application
    Filed: September 28, 2006
    Publication date: December 11, 2008
    Applicants: SB PHARMCO PUERTO RICO INC., NEUROCRINE BIOSCIENCES INC.
    Inventor: Frank Hossner
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
    Patent number: 7462625
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: December 9, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Chen Chen, Fabio C. Tucci, Zhiqiang Guo, Timothy D. Gross, Martin Rowbottom, R. Scott Struthers
  • Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
    Patent number: 7459458
    Abstract: Polymorph Form III of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide, and use thereof as a sedative-hypnotic, anxiolytic, anticonvulsant, and/or skeletal muscle relaxant agent. Related compositions and methods are also disclosed, particularly with regard to treatment of insomnia.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: December 2, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Scott E. Zook, Donald Hettinger, Henry R. DuBois, III
  • Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto
    Publication number: 20080262005
    Abstract: Compounds having utility as GnRH receptor antagonists and for treatment of a variety of sex-hormone related conditions in both men and women. Such compounds have the following structure (I): (I) wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6, R7, n and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of structure (I) in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Application
    Filed: May 13, 2005
    Publication date: October 23, 2008
    Applicant: NEUROCRINE BIOSCIENCES, INC.
    Inventors: Yun-Fei Zhu, Zhiqiang Gou, Mi Chen, Liren Zhao
  • Condensed N-heterocyclic compounds and their use as CRF receptor antagonists
    Patent number: 7427630
    Abstract: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotrophin-releasing factor (CRF).
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: September 23, 2008
    Assignees: SB Pharmaco Puerto Rico Inc., Neurocrine Biosciences Inc.
    Inventors: Romano Di Fabio, Fabio Maria Sabbatini, Yves St-Denis
  • Gonadotropin-releasing hormone receptor antagonists and methods related thereto
    Patent number: 7419983
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: September 2, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley J. Dwight, Charles Q. Huang, Fabio C. Tucci
  • Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
    Publication number: 20080194589
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Application
    Filed: October 19, 2005
    Publication date: August 14, 2008
    Applicant: NEUROCRINE BIOSCIENCES, INC.
    Inventors: Marion Lanier, Zhiyong Luo, Manisha Moorjani, John Edward Tellew, John P. Williams, Xiaohu Zhang
  • Sleep inducing compounds and methods relating thereto
    Patent number: 7393865
    Abstract: Compounds having the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts, esters and solvates thereof, wherein R1, R2, R3a, R3b, L1, L2 and n are as defined herein. Such compounds generally function as H1 receptor ligands, and thus have utility as sleep inducing agents. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: July 1, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Graham Beaton, Wilna (Willy) J Moree, Florence Jovic, Timothy Coon, Jinghua Yu
  • HYDRATE OF N-METHYL-N-(3-PHENYL)ACETAMIDE AND PROCESSES AND METHODS RELATED THERETO
    Publication number: 20080132700
    Abstract: A novel hydrate form of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide (“Compound No. 1”) and processes related to the use thereof in the synthesis of a polymorphic form of Compound No. 1.
    Type: Application
    Filed: November 30, 2007
    Publication date: June 5, 2008
    Applicant: NEUROCRINE BIOSCIENCES, INC.
    Inventors: Scott E. Zook, Donald Hettinger
  • Monoamine re-uptake inhibitors and methods relating thereto
    Patent number: 7378552
    Abstract: Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The compounds of this invention have the structure: wherein R1, R2, R3, R4, R5, R6, m, n, W, X, Y, and Z are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts, esters and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting monoamine re-uptake in a subject in need thereof.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: May 27, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Joseph Pontillo, Yinghong Gao, Warren S. Wade, Dongpei Wu, Wendy K. Eccles
  • 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
    Publication number: 20080058356
    Abstract: 4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R1 and R2 are adenosine A2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.
    Type: Application
    Filed: December 14, 2004
    Publication date: March 6, 2008
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Maria Isabel Crespo Crespo, Maria Prat Quinones, Siliva Gual Roig, Julio Cesar Castro Palomino Laria, Deborah H. Slee
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
    Patent number: 7329669
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: February 12, 2008
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Collin Regan, Jaimie K Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Q Huang
  • Crf Receptor Antagonists and Methods Relating Thereto
    Publication number: 20070293508
    Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders in mammals, including the treatment of disorders, such as stroke, manifesting hypersecretion of CRF. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Application
    Filed: December 20, 2004
    Publication date: December 20, 2007
    Applicants: SB Pharmco Puerto Rico Inc and Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc.,, SB Pharmco Puerto Rico
    Inventors: John Williams, Zhiyong Luo, John Tellew
  • Hydrate of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5?]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto
    Patent number: 7304069
    Abstract: A novel hydrate form of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide (“Compound No. 1”) and processes related to the use thereof in the synthesis of a polymorphic form of Compound No. 1.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: December 4, 2007
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Scott E Zook, Donald Hettinger
  • Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
    Patent number: 7273871
    Abstract: The present invention relates to tricyclic pyridines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof:
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: September 25, 2007
    Assignees: SB Pharmco Puerto Rico Inc., Neurocrine Biosciences Inc.
    Inventors: Romano Di Fabio, Collin F Regan, Yves St-Denis, Fabrizio Micheli, Michael K Schwaebe
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
    Publication number: 20070208049
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Application
    Filed: September 11, 2006
    Publication date: September 6, 2007
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Yun-Fei Zhu, Chen Chen, Fabio Tucci, Zhiqiang Guo, Timothy Gross, Martin Rowbottom, R. Struthers
  • GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
    Publication number: 20070191403
    Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Application
    Filed: January 25, 2007
    Publication date: August 16, 2007
    Applicant: NEUROCRINE BIOSCIENCES, INC.
    Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley Dwight, Charles Huang, Fabio Tucci